Sungjoon Chae became Co-Chief Executive Officer of Apimeds Pharmaceuticals US on October 1, 2026, per the SEC Form 3 filed November 5, 2026. A Form 3 is the first ownership report a new officer files, due within 10 days of taking the role.
Who to call at Apimeds Pharmaceuticals US, and when
A new leader at Apimeds Pharmaceuticals US brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Apimeds Pharmaceuticals US raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Apimeds Pharmaceuticals US, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Apimeds Pharmaceuticals US. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Apimeds Pharmaceuticals US
Location
100 Matawan Rd
Matawan, New Jersey, United States
About
Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin. They are focused on creating potential treatments for osteoarthritis knee pain. The company aims to offer solutions for patients who don't respond adequately to standard non-pharmacologic therapies. Apimeds is dedicated to advancing innovative therapeutic options.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Apimeds Pharmaceuticals US changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MatawanBiotechnologyHealth CareTherapeuticsBiopharma